Financials Scandinavian ChemoTech AB

Equities

CMOTEC B

SE0009242654

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm 16:29:31 10/05/2024 BST 5-day change 1st Jan Change
2.29 SEK -4.58% Intraday chart for Scandinavian ChemoTech AB +6.51% -15.19%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization 1 81.91 164.1 60.67 41.08 41.08 -
Enterprise Value (EV) 1 81.91 164.1 60.67 43.97 31.28 41.08
P/E ratio -5.72 x - -2.21 x -1.73 x - -
Yield - - - - - -
Capitalization / Revenue 57.4 x 3,349 x - 15.6 x 5.55 x 3.16 x
EV / Revenue 57.4 x 3,349 x - 15.6 x 4.23 x 3.16 x
EV / EBITDA - -11.5 x - -2.5 x -2.67 x -3.99 x
EV / FCF - - - -2.5 x - -
FCF Yield - - - -39.9% - -
Price to Book - 6.86 x - - - -
Nbr of stocks (in thousands) 6,045 9,629 12,014 17,937 17,937 -
Reference price 2 13.55 17.04 5.050 2.290 2.290 2.290
Announcement Date 08/03/21 08/03/22 07/03/23 05/03/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 1.427 0.049 - 2.822 7.4 13
EBITDA 1 - -14.26 - -17.56 -11.7 -10.3
EBIT 1 - -17.08 - -20.24 -13.7 -12.3
Operating Margin - -34,851.02% - -717.12% -185.14% -94.62%
Earnings before Tax (EBT) 1 - - - -21.09 -15.3 -12.3
Net income 1 - - -22.75 -21.09 -15.3 -12.3
Net margin - - - -747.38% -206.76% -94.62%
EPS 2 -2.370 - -2.280 -1.560 - -
Free Cash Flow 1 - - - -18 - -
FCF margin - - - -529.41% - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 08/03/21 08/03/22 07/03/23 05/03/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q1 2023 Q2 2023 Q3 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - 1.181 1.08 1.382 1.7 2 2.3 -
EBITDA 1 - -5.245 -3.319 -2.296 -2.8 -3.3 -3.2 -
EBIT 1 - -5.978 -4.026 -2.798 -3.3 -3.8 -3.7 -
Operating Margin - -506.18% -372.78% -202.46% -194.12% -190% -160.87% -
Earnings before Tax (EBT) -5.034 - - - - - - -
Net income 1 -5.034 - - - -3.7 -4.2 -4.1 -3.6
Net margin - - - - -217.65% -210% -178.26% -
EPS - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 25/05/23 15/08/23 17/10/23 07/05/24 - - - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - 4 - -
Net Cash position 1 - - - - 9.8 -
Leverage (Debt/EBITDA) - - - -0.2564 x - -
Free Cash Flow 1 - - - -18 - -
ROE (net income / shareholders' equity) - -107% - -169% - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - 2.480 - - - -
Cash Flow per Share - - - - - -
Capex - 3.33 - - - -
Capex / Sales - 6,795.92% - - - -
Announcement Date 08/03/21 08/03/22 07/03/23 05/03/24 - -
1SEK in Million
Estimates
  1. Stock Market
  2. Equities
  3. CMOTEC B Stock
  4. Financials Scandinavian ChemoTech AB